• Symptomatic implant infection #14 (5) with marked bone loss.
• Lack of teeth to chew in the 1st quadrant – #15 (4) and #16
(3).
• Mobility in tooth #17 (2).
• Marked lack of soft/hard tissue in the edentulous area
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-1-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-2-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-3-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-4-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-5-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-6-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-7-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-8-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-9-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-10-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-11-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-12-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-13-1-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-14-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-15-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-16-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-17-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-18-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-19-1-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-20-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-21-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-22-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-23-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-24-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-25-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-26-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-27-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-28-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-29-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-30-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-31-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-32-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-33-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-34-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-35-1024x768.jpg)
![](https://www.augmabio.com/wp-content/uploads/2024/06/MelazEn-36-1024x768.jpg)
• Symptomatic implant infection #14 (5) with marked bone loss.
• Lack of teeth to chew in the 1st quadrant – #15 (4) and #16
(3).
• Mobility in tooth #17 (2).
• Marked lack of soft/hard tissue in the edentulous area